UTSW

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Retrieved on: 
Wednesday, February 7, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, UTSW, Telomerase, SCLC, Interferon, Nature Communications, Clinical trial, Carcinoma, Diagnosis, Lung cancer, Orphan, Cancer, University

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications .

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications .
  • “This publication highlights a rather unique dual mechanism of action for THIO as a first-in-clinic telomere-targeted anticancer agent for potential treatment of SCLC,” said Sergei M. Gryaznov, PhD., MAIA’s Chief Scientific Officer.
  • Key findings in the published paper include:
    “With few, if any, effective treatments for small cell lung cancer, there is a widespread need for innovative therapeutic strategies.
  • The positive outcomes reported in our publication show THIO’s potential as a new therapeutic approach,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer.

Children's Health and UT Southwestern Announce Plans for Transformative New Pediatric Campus in Dallas' Southwestern Medical District

Retrieved on: 
Wednesday, February 7, 2024
Partnership, OMICS Publishing Group, UTSW, Nursing, Population growth, Science, Research, Remake, Children's Medical Center Dallas, Teaching hospital, Rodale, Inc., Medical Center, Environment, Patient, Child, Investment, Health, Mockingbird Lane, News, Training, Bed, Redbird, Professor, Organization, Hospital

DALLAS, Feb. 7, 2024 /PRNewswire/ -- Children's HealthSM and UT Southwestern Medical Center unveiled plans for a new $5 billion pediatric health campus in Dallas' Southwestern Medical District today. Spanning more than 33 acres, the new pediatric campus offers a patient-centric design that can meet the rapidly increasing need for more pediatric services from the most common to the most complex. It will serve as a joint hub for innovation, academic research and training, and the development of life-saving technologies to provide exemplary care for the youngest members of our community.

Key Points: 
  • New Multi-tower Hospital to Replace Children's Medical Center Dallas to Meet Surging Demand for Pediatric Care, Research and Training
    DALLAS, Feb. 7, 2024 /PRNewswire/ -- Children's HealthSM and UT Southwestern Medical Center unveiled plans for a new $5 billion pediatric health campus in Dallas' Southwestern Medical District today.
  • Life-changing treatments, pioneering research, and training the next generation of pediatric providers are the hallmarks of the Children's Health and UT Southwestern legacy.
  • The new pediatric campus adds to the ongoing investments Children's Health continues to make to meet the region's growing pediatric medical and surgical needs.
  • In 2025, Children's Health will occupy the second floor of the 150,000-square-foot UT Southwestern Medical Center at RedBird, part of the Reimagine RedBird development.

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Retrieved on: 
Thursday, December 14, 2023
Biology, UTSW, ALS, Multiple sclerosis, Adenosine triphosphate, Springer Nature, Medicine, Phosphorylation, NADH, CNM, NAD, Open access, Brain, University, REPAIR, Ageing, ATP, Neurodegenerative disease, Journal, Medical imaging

CNM-Au8 is an orally-delivered suspension of clean-surfaced, catalytically-active gold nanocrystals shown to have neuroprotective and neuroreparative properties in multiple preclinical models of neurodegenerative disease.

Key Points: 
  • CNM-Au8 is an orally-delivered suspension of clean-surfaced, catalytically-active gold nanocrystals shown to have neuroprotective and neuroreparative properties in multiple preclinical models of neurodegenerative disease.
  • Dr. Benjamin Greenberg, Head of Medical at Clene, said, “We believe the 10.4% increase in brain NAD+/NADH ratio to be clinically significant.
  • Other groups have shown significant deficits in brain energy metabolites associated with neurodegenerative disease.
  • Elevation of brain NAD+/NADH levels to many times the rate of loss observed in healthy aging is a significant and very promising effect.”

Wilson Bryan, M.D., Former Director of FDA CBER’s Office of Tissues and Advanced Therapies, Joins Greenleaf

Retrieved on: 
Wednesday, July 19, 2023
Consulting, Biotechnology, FDA, Professional Services, Other Health, Health, General Health, Public Policy, Pharmaceutical, Medical Devices, Government, CDER, University, Therapy, Gene, ALS, CBER, Antibody, Cerebrovascular disease, Center for Biologics Evaluation and Research, Food and Drug Administration, Multimedia, Wilson, China Biologic Products, Division, Center for Drug Evaluation and Research, Medical school, UTSW, Faculty, Neurology, Rare, Food, Pharmaceutical industry, Research, Tissue

Greenleaf Health, Inc. (Greenleaf), a leading Food and Drug Administration (FDA) regulatory consulting firm, today announces that Wilson Bryan, M.D., has joined as Executive Vice President, Drug and Biological Products.

Key Points: 
  • Greenleaf Health, Inc. (Greenleaf), a leading Food and Drug Administration (FDA) regulatory consulting firm, today announces that Wilson Bryan, M.D., has joined as Executive Vice President, Drug and Biological Products.
  • His experience enhances Greenleaf’s cell and gene therapy capabilities and brings added perspective to the firm’s strategic advising on drug, biologic, and medical device regulation more broadly.
  • As a neurologist and neuromuscular specialist, Wilson deepens Greenleaf’s expertise in those fields as well.
  • Wilson received his medical degree from the University of Chicago Pritzker School of Medicine.

Cambrian Bio Launches Telos Biotech to Enable More Robust Cell Therapies

Retrieved on: 
Tuesday, June 27, 2023
Maintenance, Malignancy, Ageing, Cancer, Research, Cell, Doctor of Philosophy, Cell biology, Patient, Biology, UTSW, Vaccine, University of Texas Southwestern Medical Center, Telos, DRS

NEW YORK, June 27, 2023 /PRNewswire/ -- Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, today announced the launch of its new pipeline company, Telos Biotech. The organization will develop Telovance ™, a novel recombinant protein delivered intracellularly during the ex-vivo manufacturing of CAR-T cells.

Key Points: 
  • During this process, critically shortened telomeres have emerged as a key barrier to successful CAR-T cell immunotherapy.
  • By safely lengthening telomeres during the ex-vivo manufacturing process, Telos can rewind the cellular biological clock and unlock the potential of cell immunotherapy.
  • With these findings, Telos has engineered Telovance ™, a recombinant protein that can be easily incorporated into the cell therapy manufacturing process.
  • "At Telos, we believe that we have overcome those limits and are now able to safely maintain and lengthen telomeres to create a more robust and fit cell."

FDA clears ImageBiopsy Labs' latest AI-powered Software for a comprehensive Set of Automated Measurements on Long Leg Radiographs

Retrieved on: 
Friday, June 23, 2023
University of Texas Southwestern Medical Center, Surgeon, University, Hip, Elective surgery, Deep learning, DICOM, Spine, Leg, MBA, LAMA, Radiology, Professor, X-ray, MD, Patient, Fracture, MSK, UTSW, Principal, FDA, Hand, Knee, Medical device, Medical imaging

The company previously FDA-cleared its IB Lab KOALA Knee-Osteoarthritis Labeling Assistant and intends to expand to the US with further MSK-focused software solutions.

Key Points: 
  • The company previously FDA-cleared its IB Lab KOALA Knee-Osteoarthritis Labeling Assistant and intends to expand to the US with further MSK-focused software solutions.
  • Nearly two million joints are replaced every year worldwide and that number is set to double by the end of the decade.
  • Accurate and standardized measurements to assess the lower leg geometry are critical before and after surgery.
  • Additionally, ImageBiopsy Lab now offers fracture detection, further enhancing their comprehensive range of solutions.

Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis

Retrieved on: 
Thursday, May 25, 2023
Translation, University, Cohort, CNM, National Multiple Sclerosis Society, Neurodegenerative disease, Agonal respiration, Brain, Multiple sclerosis, SALT, Remyelination, MS, Regeneration, Translational medicine, RRMS, Patient, UTSW, Pharmaceutical industry, Medical imaging, Medical device, Research

The one-year grant will fund Cohort 2 of REPAIR-MS, a Phase 2 clinical study investigating target engagement of CNM-Au8 in patients with non-active progressive MS.

Key Points: 
  • The one-year grant will fund Cohort 2 of REPAIR-MS, a Phase 2 clinical study investigating target engagement of CNM-Au8 in patients with non-active progressive MS.
  • Benjamin Greenberg, M.D., a Professor and Vice Chair of Clinical & Translational Research at UTSW, is not affiliated with this project.
  • “Our previous REPAIR-PD and REPAIR-MS (Cohort 1) studies demonstrated target engagement with CNM-Au8 treatment in both patients with Parkinson’s Disease and in patients with relapsing remitting multiple sclerosis (RRMS).
  • "We are eager to see the brain biomarker results from CNM-Au8 treatment in people living with non-active progressive MS from this study".

TCN Continues Global Growth with New Offices in the U.K. and Romania, Further Expanding its Footprint in the Contact Center Technology Market

Retrieved on: 
Tuesday, May 23, 2023
University, City centre, TCN, Microsoft, UTSW, Software, Tutoring, EU

ST. GEORGE, Utah, May 23, 2023 /PRNewswire-PRWeb/ -- TCN, Inc., a global provider of a comprehensive cloud-based call center platform for enterprises, contact centers, BPOs and collection agencies, today announced that it has hit significant milestones in overall growth globally. Continuing its growth trajectory, TCN achieved nearly 25% year-over-year revenue growth globally during 2022 while also expanding its North American employee base by nearly 20%. Additionally, the employee numbers continued to grow in other markets as the U.K./EU employee numbers doubled in 2022. Earlier this year, TCN opened an office in the Midlands regions of the U.K. and an EU head office in Bucharest, Romania and hired seasoned industry professionals in both Europe and the U.K. to better serve EU and U.K. contact centers.

Key Points: 
  • Continuing its growth trajectory, TCN achieved nearly 25% year-over-year revenue growth globally during 2022 while also expanding its North American employee base by nearly 20%.
  • Focused on developing and introducing technology solutions to improve efficiency and productivity for its clients, TCN has continued to maintain its position as a global technology leader in the contact center industry.
  • "Last year was momentous for TCN on all fronts," said Terrel Bird, CEO and co-founder at TCN.
  • TCN opened an office in the U.K. to better serve its clients and further drive business development in the country.

Research Bridge Partners and Lyda Hill Philanthropies Support Life Science Spinouts At UT Southwestern Medical Center

Retrieved on: 
Monday, April 24, 2023
National academy, Partnership, Public health, Education, AUC, Research, Partner, Biotechnology, University, Biomedical Research, LHP, Bangladesh Technical Education Board, Science, Organization, Silicon, Entrepreneurship, National Academy of Medicine, Publishing, Investment, UTSW, Pharmaceutical industry, Management, University of Texas Southwestern Medical Center, Family

Following the initial funding and expertise offered by both Research Bridge Partners and UT Southwestern's Office for Technology Development, subsequent investments will be raised through special purpose vehicles.

Key Points: 
  • Following the initial funding and expertise offered by both Research Bridge Partners and UT Southwestern's Office for Technology Development, subsequent investments will be raised through special purpose vehicles.
  • The initiative will also include bespoke high-impact advisory sessions and ad hoc strategic support for early-stage researchers at UT Southwestern.
  • UT Southwestern, one of the nation's premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education.
  • "When Isaac and I established Research Bridge Partners, we did so with institutions like UT Southwestern in mind," said Research Bridge Partners Co-Founder and Chairman Reid Hoffman.

Globe Life Inc. Renews Endowment to UT Southwestern Medical Center

Retrieved on: 
Thursday, March 23, 2023
Public health, Education, AUC, GL, Research, Physician, Nursing, UTSW, Health, NYSE, University of Texas Southwestern Medical Center

MCKINNEY, Texas, March 23, 2023 /PRNewswire/ -- Globe Life Inc. (NYSE: GL) today announced it will renew its endowment to UT Southwestern Medical Center, one of the premier academic medical centers in the nation.

Key Points: 
  • MCKINNEY, Texas, March 23, 2023 /PRNewswire/ -- Globe Life Inc. (NYSE: GL) today announced it will renew its endowment to UT Southwestern Medical Center, one of the premier academic medical centers in the nation.
  • As part of its purpose-driven mission to help Make Tomorrow Better, Globe Life has pledged $300,000 in support of the organization.
  • Since 2013, Globe Life has provided an endowment in the Department of Family and Community Medicine at UT Southwestern.
  • Endowment deposits are placed in the Globe Life Community Medicine Fund and are used for funding family medicine initiatives led by UT Southwestern.